博鳌乐城管理局局长傅晟： 为中国医疗健康事业书写"乐城方案" 为了进一步提升政策的适用性，我们还组建了由权威院士专家领衔的"国际创新药械技术引进专家 委员会"，建立更科学高效的境外产品评估引进机制。联合首批11家国内顶尖医疗机构及企业成立"乐城 国际创新药械医疗联合体"，探索"接诊在当地，治疗在乐城，随访回属地，数据可共享"协作模式，推 动乐城创新药械惠及更多患者。 我们还连续6年推出"乐城全球特药险"。自2021年起，与全国77个商业保险项目合作，总参保人数 累计超1亿人次;并与安盛香港等国际保险公司合作，打通跨境医疗保险支付流程。 打造具有国际影响力的医疗科技创新平台，更需凝聚全球智慧。不久前，乐城首届全球创新药械博 览会吸引近80家国外药械企业负责人参会，他们纷纷表示坚定看好海南自贸港和乐城的发展前景，将进 一步加大投资合作力度。 随着全岛封关运作的正式启动，乐城也将迎来从"政策高地"迈向"人才高地""产业高地"的重大机 遇。面向未来，乐城将坚持"医、药、研、产、城"一体化发展，打造守护安康的"健康之城"，点燃生命 的"希望之城"，成就幸福的"快乐之城"，朝着建设成为世界一流的国际医疗旅游目的地和医疗科 ...

博鳌乐城打造全球医疗资源交汇"超级接口" 开放窗口拓先河 医疗旅游筑高地 本版AI图/陈海冰 俯瞰博鳌乐城国际医疗旅游先行区。海南日报全媒体记者 袁琛 摄 经济要发展，健康要上去。人民群众的获得感、幸福感、安全感都离不开健康。要大力发展健康事业， 为广大老百姓健康服务。 患者在乐城一家医院接受检查。海南日报全媒体记者 袁琛 摄 医疗旅游 嘉宾观摩乐城"永不落幕"国际创新药械展。海南日报全媒体记者 王程龙 摄 中国国际消费品博览会上的乐城展馆。海南日报全媒体记者 袁琛 摄 海南日报全媒体记者 李豌 琼州潮涌，东风浩荡。十二载耕耘，一枚"医疗特区"的种子，在博鳌乐城破土而出、拔节生长，终成繁 荫。 从"特许引进"到"同步使用"，从"患者追药"到"药等患者"，如今，博鳌乐城国际医疗旅游先行区已实现 从政策"试验田"到产业"新高地"的蝶变。琼岛东岸这片20平方公里的土地，已不仅是国际创新药械落地的"中 国窗口"，更是全球医疗资源交汇的"超级接口"。 乐城首届全球创新药械博览会上，100款国际创新药械、特医食品及生物医学新技术集中发布，让一家美 国企业的高管由衷感慨："这里许多新产品让我大开眼界!" 建设12年来，乐城 ...

浦东生物医药产业整体人才紧缺程度有所缓解，但着眼于新兴赛道和未来产业，免疫/细胞人才、 抗体/RNA/核药研发人才、AI复合型人才和生物合成技术人才的需求突显。 生物医药从业人员总量稳中有升。2023年浦东相关从业人员总量12.91万人，占全市45.9%；2024年 浦东相关从业人员总量12.99万人，占全市46.0%。2024年产业人才新进率为16.3%，离职率为15.6%，产 业人才数量整体保持稳定，呈现一定程度扩张。 博士学历占比突出。浦东生物医药行业博士学历占比达5.0%，领先三大先导产业均值2.6%，其中 张江生物医药博士学历占比达到5.9%。从子产业来看，医药研发服务从业人员的硕博人才占比为 36.7%，在各子产业中最高。 40周岁以下青年从业人员占比超六成。今年4月，《浦东新区关于支持青年人才创新创业的若干措 施》正式发布，重点推出"两个100万"政策，即100万平方米低租金青年公寓与100万平方米低租金创业 空间。可以预见的是，未来生物医药产业青年人才将进一步集聚。 浦东通过全球名校人才直通车、全球引才伙伴计划、"浦东国际人才驿站"等多渠道吸引人才。目 前，产业留学人才呈回流趋势。留学人才占比 ...

Core Insights - The first Global Innovation Drug and Medical Device Expo was held in Boao, Hainan, showcasing the significance of the event in the medical tourism sector [1] - The authoritative "White Paper on the Introduction and Use of International Innovative Drugs and Medical Devices in the Boao Lecheng International Medical Tourism Pilot Zone" was released, highlighting the region's role in medical innovation [1] Summary by Sections - **Innovative Products**: The white paper includes over 100 innovative drug and medical device products, special medical foods, health foods, and biomedical technology projects introduced in the Lecheng Pilot Zone [1] - **Patient Cases**: Real patient cases were documented, demonstrating the effectiveness and quality of life improvements from treatments received in the Lecheng area [1] - **Framework of the White Paper**: The white paper is structured around six core sections, covering international drug and device approvals, licensed imports, treatment effect case studies, real-world data applications, local production, and future introduction plans [1] - **Unique Value Proposition**: The document outlines Lecheng's unique value as a testing ground and window for medical innovation in China [1]

Core Viewpoint - China's ongoing deepening of open practices has transformed into tangible opportunities, enhancing the local medical innovation ecosystem and attracting global expertise while promoting Chinese innovation on a global scale [1] Group 1: Government Initiatives and Market Opportunities - Premier Li Qiang emphasized that the China International Import Expo (CIIE) serves as a vital bridge connecting the Chinese economy with the world, showcasing the vitality of China's vast market [1] - The number of participating companies at this year's CIIE reached a historical high, reflecting the robust dynamism of China's super-large market [1] - China is committed to high-level opening-up, providing clearer policy directions and stable expectations for foreign enterprises operating in China [1] Group 2: Corporate Responses and Investments - Executives from various pharmaceutical and medical device companies expressed encouragement from the Premier's speech, viewing CIIE as a crucial platform for foreign enterprises to connect deeply with the Chinese market [2] - AstraZeneca announced a $2.5 billion investment in Beijing, establishing a new global strategic R&D center to enhance drug discovery and clinical development [2] - Boehringer Ingelheim highlighted its commitment to innovation in China, marking its 30th anniversary in the market and emphasizing the supportive policies for biopharmaceutical innovation [3] Group 3: Long-term Commitment to China - Sanofi views China as a key strategic market and is optimistic about the future of the healthcare sector, having recently launched a new insulin raw material project in Beijing [4] - GE Healthcare has introduced over 50 precision medical innovations from the expo to clinical settings, indicating a strong commitment to the Chinese market [8] - Johnson & Johnson Medical Technology has been a witness and participant in China's healthcare modernization, aligning its strategies with China's support for industrial innovation [7]

Core Insights - Hainan Boao Lecheng International Medical Tourism Pilot Zone is recognized as China's only medical special zone, serving as a "tax-free paradise" for health care and a key channel for international innovative drugs and medical devices to enter the Chinese market [1] - The zone has established partnerships with over 180 pharmaceutical and medical device companies from 20 countries and regions, introducing 512 types of international innovative drugs and devices, benefiting more than 180,000 patients [1] - The average annual medical flow population in Lecheng is around 30%, indicating a significant influx of patients seeking advanced medical care [1] Group 1 - Lecheng is not only a cluster of hospitals but also an international health destination integrating "medicine, pharmaceuticals, research, wellness, and tourism" [1] - The zone has collaborated with local areas in Hainan, such as Qionghai and Wanning, to launch over 20 medical travel routes, achieving resource synergy [1]

Group 1 - Jiangsu has been advancing the "Quality Jiangsu" initiative, optimizing quality supply across the province, with multiple indicators ranking first nationally, thereby strengthening the economic foundation [1] - The province has initiated the 2025 Provincial Quality Award evaluation, focusing on key industrial chains with 15 quality comparison and tackling projects, and involving 29 counties in quality enhancement activities [1] - Jiangsu has established a brand protection mechanism, aiding key enterprises like Nanjing Yunjin Research Institute and Bosideng Group in successfully safeguarding their brands, with 11 brands selected as the first batch of Chinese consumer brands, the highest in the country [1] Group 2 - The province has revised the "Jiangsu Provincial Agricultural Product Quality Safety Regulations" and is exploring traceability for key industrial products, collecting over 534,000 pieces of information on electric bicycle production [2] - Jiangsu has launched a three-year action plan to optimize the consumer environment, establishing 13 provincial-level consumer education experience stations and adding 3,000 offline no-reason return merchants [2] - The province has seen the addition of 2,139 chief quality officers in enterprises this year, with financing support for over 9,700 companies amounting to nearly 40 billion yuan [2] Group 3 - A favorable ecosystem is forming in Jiangsu, driven by industrial demand, leading enterprises, international market benchmarking, and financial support, as highlighted in the recent China Quality (Nanjing) Conference [3] - The Jiangsu Market Supervision Bureau is coordinating efforts to build quality platforms, promoting high-quality products and services to flow freely in broader markets [3]

Core Viewpoint - Boao Lecheng International Medical Tourism Pilot Zone will showcase a range of cutting-edge international medical devices and special foods at the 8th Hainan International Health Industry Expo, highlighting its role as a "medical special zone" for innovative healthcare solutions [2][3] Group 1: Exhibition Highlights - The expo will feature international advanced medical technologies and products that are not yet available in China, including a heart pacemaker with a battery life of nearly 17 years, an allergy treatment drug used in multiple countries, a groundbreaking smart cochlear implant system, and a non-invasive ADHD treatment system [2] - Lecheng has established partnerships with over 180 pharmaceutical and medical device companies from 20 countries and regions, introducing 512 types of international innovative medical products for the first time in China, covering key areas such as oncology, rare diseases, ophthalmology, cardiovascular health, rehabilitation, and aesthetic medicine [2] Group 2: Industry Impact - The Hainan International Health Industry Expo has become an important platform for showcasing policy benefits, gathering international resources, and promoting industry connections [3] - Boao Lecheng aims to deepen exchanges and expand cooperation with global health industry partners through the expo, exploring new pathways for medical technology innovation and transformation [3]

Group 1 - China's aviation engine "Taihang 2" pure hydrogen gas turbine has achieved a cumulative operation time of over 7000 hours for the first unit and over 5000 hours for the second unit, marking a successful commercialization of the 2MW pure hydrogen gas turbine [2] - The low-altitude economy is driving the popularity of drone pilots, with over 225,000 registered drone pilot licenses in China as of June 2024, and more than 2000 training institutions available [3] - Shenzhen has established its first pharmaceutical and medical device industry overseas joint venture, aiming to create a platform for local companies to connect with global markets [4] Group 2 - China's marine economy has surpassed 10 trillion yuan for the first time, showing a growth of 5.9% compared to the previous year, with the marine engineering equipment manufacturing sector maintaining the largest global market share for seven consecutive years [5] - The first large-scale lithium-sodium hybrid energy storage station in China has been put into operation, with a capacity of 400 MWh and a green energy ratio of 98% [6] - The Yukun high-speed railway's Ningjingli tunnel has been safely completed, contributing to the construction of the railway with 40 tunnels already completed in the Yunnan section [7][8] Group 3 - Yunding Technology has launched an industrial vision intelligent all-in-one machine in collaboration with Ascend, featuring high computing power and supporting over 100 channels of 1080P video processing [9] - A Chinese team has overcome challenges in the large-scale production of third-generation photovoltaic technology, achieving stable mass production of perovskite solar cells [10] - QQ Browser has introduced an AI tool named "AI Gao Kao Tong" to assist students in exam preparation and college application processes [11] Group 4 - Market rumors suggest that Sais Technology's humanoid robot prototype is ready for demonstration, although the company has not confirmed this information [12] - U.S. President Trump has threatened to impose tariffs of 50% on the EU and 25% on Apple, causing declines in Apple stock and U.S. stock futures [13] - Experts have commented on the impracticality of relocating iPhone production to the U.S., citing high costs and potential price increases for consumers [14] Group 5 - Japan's consumer price index for rice has seen a dramatic increase of 98.4% year-on-year in April, marking the highest increase since 1971 [15] - Nissan is considering selling its Yokohama headquarters as part of its restructuring plan, which may incur an additional 60 billion yen (approximately 418 million USD) in costs [16] - Elon Musk praised Google's new AI video generation model, Veo 3, during a developer conference, while also announcing his return to a 24/7 work schedule [17]

Core Insights - The establishment of Shenzhen's first pharmaceutical and medical device industry overseas joint venture aims to connect local companies with global markets, enhancing export capabilities [1] - Shenzhen is a leader in high-end medical device exports, with significant metrics ranking it among the top in the country [1] - In 2024, Shenzhen's pharmaceutical and medical device industry is projected to have the highest export total among major cities, accounting for 12.9% of the national total [1] Group 1 - The joint venture consists of manufacturers, professional service institutions, and industry associations [1] - The initiative is part of Shenzhen's "Double Hundred Action" to accelerate the overseas expansion of its pharmaceutical and medical device sectors [1] - The joint venture aims to create an accelerator for local pharmaceutical and medical device companies to explore international markets [1] Group 2 - Shenzhen's performance in the high-end medical device export sector is highlighted as particularly strong [1] - The city's export total for the pharmaceutical and medical device industry is expected to lead among major cities in 2024 [1] - The national export share of Shenzhen's pharmaceutical and medical device industry is projected to be 12.9% [1]